Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Until that data becomes available, the Phase 2 results showing no thyroid safety signals, combined with the broader class experience, suggest the thyroid concern does not materially differ between GLP-1 medications
How This Works IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity to IGF binding proteins [1]
They work by mimicking a hormone called glucagon-like peptide-1 that regulates insulin and glucose levels
10.1016/j.envexpbot.2007.06.007 191 ValpuestaV.BotellaM
Results depend on a patients lifestyle, activity level, genetics, and metabolism
A decision from the FDA is expected by spring 2026
